Corcept Therapeutics (NASDAQ:CORT) Stock Rating Upgraded by Truist Financial

Key Points

• Truist Financial upgraded Corcept to a "strong‑buy", though analyst opinions are mixed and the MarketBeat consensus remains a Hold with an average target of $76.00.
• FDA approval of Lifyorli (relacorilant) plus nab‑paclitaxel for platinum‑resistant ovarian cancer sparked a sharp rally and trading volatility (shares rose ~19.7% intraday), a move amplified by a director buying 100,000 shares at about $33.14.
• Recent quarterly results missed estimates (EPS $0.20 vs $0.33 expected; revenue $202.1M vs $254.9M) and the company faces securities‑class‑action lawsuits and patent/regulatory risks that could weigh on the stock.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) was upgraded by analysts at Truist Financial to a "strong-buy" rating in a research report issued on Wednesday,Zacks.com reports.

A number of other research analysts have also recently commented on the stock. Weiss Ratings reiterated a "hold (c)" rating on shares of Corcept Therapeutics in a research report on Monday, December 29th. HC Wainwright lowered their price objective on shares of Corcept Therapeutics from $67.00 to $60.00 and set a "buy" rating for the company in a report on Wednesday. Wolfe Research cut shares of Corcept Therapeutics from a "peer perform" rating to an "underperform" rating and set a $30.00 price objective for the company. in a research note on Wednesday, December 31st. UBS Group started coverage on shares of Corcept Therapeutics in a report on Tuesday, December 16th. They set a "neutral" rating and a $95.00 target price on the stock. Finally, Canaccord Genuity Group lifted their target price on shares of Corcept Therapeutics from $99.00 to $100.00 and gave the stock a "buy" rating in a research report on Friday, January 23rd. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have assigned a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Hold" and a consensus target price of $76.00.

Corcept Therapeutics Trading Up 19.7%

Shares of CORT stock opened at $40.47 on Wednesday. The business has a 50-day moving average price of $37.41 and a two-hundred day moving average price of $61.15. Corcept Therapeutics has a 12-month low of $28.66 and a 12-month high of $117.33. The company has a quick ratio of 2.85, a current ratio of 2.92 and a debt-to-equity ratio of 0.01. The firm has a market cap of $4.30 billion, a P/E ratio of 49.35 and a beta of 0.29.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last announced its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.20 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.13). The firm had revenue of $202.13 million for the quarter, compared to the consensus estimate of $254.94 million. Corcept Therapeutics had a net margin of 12.96% and a return on equity of 15.19%. Corcept Therapeutics's revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter last year, the company posted $0.26 earnings per share. Equities analysts anticipate that Corcept Therapeutics will post 1.36 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director G Leonard Baker, Jr. bought 100,000 shares of the business's stock in a transaction dated Tuesday, March 17th. The shares were purchased at an average price of $33.14 per share, for a total transaction of $3,314,000.00. Following the completion of the acquisition, the director owned 1,146,631 shares of the company's stock, valued at approximately $37,999,351.34. This trade represents a 9.55% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider William Guyer sold 20,000 shares of the firm's stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $40.87, for a total transaction of $817,400.00. Following the completion of the transaction, the insider owned 1,235 shares in the company, valued at $50,474.45. This represents a 94.18% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 60,000 shares of company stock worth $2,241,035 over the last ninety days. Insiders own 20.80% of the company's stock.

Institutional Investors Weigh In On Corcept Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Royal Bank of Canada grew its holdings in Corcept Therapeutics by 18.9% in the 1st quarter. Royal Bank of Canada now owns 15,385 shares of the biotechnology company's stock worth $1,757,000 after acquiring an additional 2,444 shares during the last quarter. Amundi bought a new position in shares of Corcept Therapeutics during the first quarter valued at about $450,000. NewEdge Advisors LLC bought a new position in shares of Corcept Therapeutics during the first quarter valued at about $518,000. Cetera Investment Advisers boosted its holdings in shares of Corcept Therapeutics by 32.9% during the second quarter. Cetera Investment Advisers now owns 11,129 shares of the biotechnology company's stock worth $817,000 after purchasing an additional 2,755 shares during the period. Finally, Legal & General Group Plc grew its stake in shares of Corcept Therapeutics by 10.6% in the second quarter. Legal & General Group Plc now owns 298,822 shares of the biotechnology company's stock worth $21,934,000 after purchasing an additional 28,685 shares during the last quarter. Hedge funds and other institutional investors own 93.61% of the company's stock.

Corcept Therapeutics News Roundup

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: FDA approval of Lifyorli (relacorilant) plus nab‑paclitaxel for platinum‑resistant ovarian cancer — key commercial catalyst and the immediate driver of the rally; approval was completed ahead of schedule and trial data showed a survival benefit. FDA Approves Corcept's Lifyorli (BusinessWire)
• Positive Sentiment: Coverage/analyst support: H.C. Wainwright reiterated a Buy and published a $60 price target (lowered from $67) while calling the early approval and long‑term sales outlook supportive — helps justify upside expectations despite the lower PT. Corcept Wins FDA Approval (TipRanks)
• Positive Sentiment: Insider/director buying noted in mid‑March (100,000 shares) has been cited by market commentary as a confidence signal and likely amplified bullish positioning ahead of the approval. Insider Buy & Catalyst Analysis (QuiverQuant)
• Neutral Sentiment: Trading was temporarily halted earlier today for a LULD pause as the stock moved sharply — a market‑structure response to volatility, not company news. (Trading halt reported in market feeds.)
• Neutral Sentiment: Some outlets reported very large intraday moves (30–48%+ intraday prints) as traders re‑priced the stock on the approval; expect continued volatility and large volume in the near term. Market Reaction Coverage (Reuters)
• Negative Sentiment: Multiple law firms have filed/alerted investors about securities‑class‑action suits alleging prior disclosures and regulatory/patent issues — these lawsuits and related allegations (including references to an FDA rejection and court patent loss in filings) represent material legal and financial risk that could pressure the stock. Hagens Berman Securities Class Action Alert (GlobeNewswire)
• Negative Sentiment: Recent insider selling: a disclosed sale by William Guyer on March 20 reduces insider ownership and may be viewed unfavorably by some investors (though offset by the director buy referenced above). Insider Sale SEC Filing

About Corcept Therapeutics

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company's scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company's flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing's syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.